Zhao 2016.

Methods	Study design: Randomised clinical trial Study duration: January 2010 to December 2012 Duration of follow‐up: 29‐62 months Setting: Hospital
Participants	Age (mean ± SD): TACE + RFA: 65.89 ± 9.3 years; TACE alone: 66.85 ± 9.35 years Male (n/total): TACE + RFA: 37/ 47; TACE alone: 34/ 47 Child‐Pugh Class (patients): Class A: TACE + RFA: 45; TACE: 44 Class B: TACE + RFA: 2; TACE: 3
Interventions	TACE + RFA group (n = 47): TACE: Chemotherapeutic drugs: 5‐fluorouracil 0.25‐1 g, theprubicin 30‐50 mg, and oxaliplatin 100‐150 mg RFA: The interval between TACE and RFA was 2 weeks. CT‐guided RFA. HGCF‐3000 ablation system, output power of 60 W TACE group (n = 47): Chemotherapeutic drugs: 5‐fluorouracil 0.25‐1 g, theprubicin 30‐50 mg, and oxaliplatin 100‐150 mg
Outcomes	1‐, 3, and 5‐year survival rates Adverse events
Notes	Country of study: China Source of funding: None There was insufficient information available to satisfactorily determine the method of randomisation and the study data could not be verified. We have attempted to contact the study authors for more information, but so far, we have not been successful in doing this.